When a single drug goes from a $1.2 billion product in 2023 to a $5-billion-plus annual run-rate by mid-2026, the market usually stops treating the company as a biotech “story stock” and starts pricing it as a durable compounder. That transition is exactly what is happening with argenx SE (NASDAQ: ARGX), the Netherlands-headquartered immunology company behind VYVGART (efgartigimod). In the second quarter of 2026, argenx reported $1.5 billion in product net sales, up 60% year-over-year — its 18th consecutive quarter of sequential growth — and swung to an operating profit of $494 million, up 146% from a year earlier. The stock, at $1,032.58, sits within striking distance of its 52-week high of $1,039.30, and a wave of post-earnings analyst target increases (RBC to $1,025, Leerink to $1,065, Guggenheim to $1,185, Wells Fargo to $1,350) has reset the bull case.
This is the argenx VYVGART franchise expansion thesis in a sentence: a first-in-class FcRn antibody platform is graduating from a single-indication myasthenia gravis drug into a multi-indication, multi-billion-dollar autoimmune platform, and it is doing so while generating a 32.8% net margin and carrying almost no debt. The question for investors in 2026 is no longer “will VYVGART work” — it clearly does — but “how much of the future growth is already in the $64.6 billion market cap, and what pipeline optionality remains uncounted.”
Three investment points frame this analysis. First, the moat is a validated biology platform, not a single molecule. argenx pioneered FcRn (neonatal Fc receptor) inhibition, and VYVGART’s real-world durability across generalized myasthenia gravis (gMG), CIDP, and now seronegative gMG demonstrates switching costs and physician habit that new entrants must overcome. Second, the financial inflection is real and accelerating. argenx has crossed from cash-burning clinical-stage biotech to a profitable, self-funding commercial engine with an 89% gross margin and a debt-to-equity ratio of 0.01. Third, the valuation is demanding but not unhinged — at 26.9x forward earnings on consensus EPS of $38.44, argenx trades at a growth-adjusted multiple that looks reasonable against 60% top-line growth, provided the pipeline delivers.
This article covers the company’s business model and revenue mix, the structure and growth trajectory of the FcRn and broader autoimmune market, argenx’s competitive moat and its durability against J&J and UCB, a full financial analysis, a valuation with bull/base/bear scenarios, the key risks, and a concrete exit plan for both new and existing holders.
—
1. Company Overview
argenx SE is a global immunology company that discovers, develops, and commercializes antibody-based therapies for severe autoimmune diseases. Its business model is straightforward in structure but unusually powerful in economics: argenx owns a proprietary antibody engineering platform, uses it to create differentiated biologics, runs them through registrational trials across multiple rare and severe autoimmune indications, and then commercializes them directly through its own specialty sales infrastructure in the U.S., Europe, Japan, and China. Because these are specialty biologics for defined patient populations treated by a concentrated set of neurologists and immunologists, argenx captures the vast majority of the drug’s economics rather than sharing them with a large partner.
Revenue is overwhelmingly driven by the VYVGART franchise — efgartigimod, sold as intravenous VYVGART and as the subcutaneous VYVGART Hytrulo (prefilled syringe and, from 2027, an autoinjector). VYVGART is an antibody fragment that targets FcRn, the receptor responsible for recycling immunoglobulin G (IgG) antibodies. By blocking FcRn, VYVGART accelerates the breakdown of disease-causing IgG autoantibodies, lowering their levels and reducing autoimmune attack. This mechanism is indication-agnostic: any disease driven by pathogenic IgG is a potential target, which is why one molecule can address a widening set of indications.
The approximate revenue mix by indication and geography reflects a franchise still early in its expansion:
Revenue driver Role in the mix Trajectory VYVGART / VYVGART Hytrulo — gMG Largest contributor; original approval (U.S. Dec 2021) Mature launch, still growing on new patient starts VYVGART Hytrulo — CIDP Second major indication Rapid ramp; large addressable population VYVGART — seronegative gMG Newest indication expansion Early — incremental patient pool Geography: United States Majority of net sales Core engine, deep penetration Geography: Japan, EU, China Growing international base Long-tailed multi-year growth
In Q2 2026, product net sales reached $1.5 billion, and trailing-twelve-month total revenue was $5.22 billion. The subcutaneous formulation is a critical part of the mix because it moves treatment from infusion centers to self-administration, expanding the treatable population and improving persistence.
In terms of market position, argenx is the first-mover and market leader in FcRn inhibition. It defined the category with efgartigimod and retains the broadest approved label footprint (gMG, CIDP, and seronegative gMG), the most real-world experience, and the deepest commercial infrastructure among FcRn players. Competitors UCB (RYSTIGGO/rozanolixizumab) and Johnson & Johnson (IMAAVY/nipocalimab, approved April 2025) entered later and are working to catch up on indications and prescriber relationships.
On ownership and governance, argenx is a widely held company with substantial institutional ownership typical of a large-cap biopharma, and management has articulated a long-range “Vision 2030” framework targeting a broad set of labeled indications and tens of thousands of treated patients. The near-total absence of debt (debt-to-equity of 0.01) means the capital structure is equity-driven, aligning management incentives with shareholders and removing balance-sheet risk from the equation.
—
2. Industry Analysis
2-1. Market Size & Growth Trajectory
argenx sits at the intersection of two large and growing markets: the FcRn inhibitor market specifically, and the broader autoimmune/IgG-mediated disease market generally. The autoimmune therapeutics market globally runs into the tens of billions of dollars annually and spans dozens of diseases — myasthenia gravis, CIDP, ITP, pemphigus, myositis, lupus nephritis, and many more — that share a common feature: pathogenic IgG autoantibodies. Industry analysts covering the FcRn category (including DelveInsight and multiple market-research houses) consistently model rapid, double-digit growth over the coming decade as FcRn inhibitors expand from a handful of approved indications toward the 20-plus autoimmune conditions where the mechanism is biologically plausible.
The FcRn class itself is still in an early-growth-to-acceleration phase of its cycle. VYVGART only launched commercially in the U.S. in December 2021, meaning the category is barely four years into commercialization. The generalized myasthenia gravis market — the beachhead indication — is itself expanding as FcRn inhibitors, complement inhibitors, and targeted immunology options together displace older, less-targeted therapies like chronic steroids and broad immunosuppressants. Each new indication (CIDP, seronegative gMG, and the myositis and other readouts pending) opens a fresh patient pool that was previously untreated or poorly served, effectively resetting the growth runway.
The key point for investors is that argenx’s 60% year-over-year growth is not coming from a mature, saturated market. It is coming from a category in the steep part of its adoption S-curve, where the total addressable population is being expanded by both geographic rollout and indication expansion simultaneously.
2-2. Structural Growth Drivers
Driver 1 — Indication expansion of a single validated molecule. The most powerful structural driver is that VYVGART’s FcRn mechanism is disease-agnostic across IgG-mediated conditions. Each new approved indication adds an incremental patient pool without requiring a new drug discovery cycle, a new safety database from scratch, or a new commercial channel — the same neurologists and immunologists who already prescribe VYVGART for gMG treat CIDP and seronegative patients too. This creates a compounding effect: the marginal cost of capturing the next indication’s patients is far lower than the first, because the infrastructure, safety profile, and prescriber trust already exist. With registrational readouts pending in autoimmune myositis (3Q26) and the empasiprubart MMN study (4Q26), plus a long list of earlier-stage programs, the indication pipeline is the single most important long-term value creator. Over a 5–10 year horizon, this is what converts a myasthenia gravis drug into an autoimmune platform.
Driver 2 — Subcutaneous and self-administration convenience. The shift from intravenous infusion to subcutaneous VYVGART Hytrulo — first as a prefilled syringe (a new prefilled-syringe administration route for gMG and CIDP was approved in March 2026) and, planned for 2027, as an autoinjector for all approved indications — is a structural expander of both the addressable population and treatment persistence. Self-injection removes the burden of infusion-center visits, opening treatment to patients who would not tolerate or access IV therapy, improving adherence, and lengthening the duration each patient stays on drug. In specialty biologics, convenience is not a cosmetic feature; it directly drives net sales by increasing both patient starts and time-on-therapy. This is a short-to-medium-term driver that is already contributing and will accelerate through the 2027 autoinjector launch.
Driver 3 — Geographic penetration outside the United States. While the U.S. is the largest and most mature market, argenx’s international footprint in Japan, the EU, and China remains comparatively early. Reimbursement timelines, country-by-country launches, and building specialty commercial teams in each geography create a multi-year runway of new-market growth that is largely independent of U.S. dynamics. As each major market clears reimbursement for each indication, a new leg of growth turns on. This is a long-term driver that provides diversification: even if U.S. gMG penetration matures, ex-U.S. rollout and new-indication launches can sustain double-digit franchise growth.
2-3. Competitive Landscape
The FcRn and adjacent myasthenia gravis market has turned genuinely competitive, with FcRn inhibitors, complement inhibitors, and targeted immunology options all vying for share. The most direct competitors are other FcRn players.
Company Product / candidate Positioning vs. argenx Status argenx VYVGART / VYVGART Hytrulo (efgartigimod) First-mover, broadest label (gMG, CIDP, seronegative gMG), SC autoinjector coming 2027 Approved & leading UCB RYSTIGGO (rozanolixizumab) Covers AChR+ and MuSK+ gMG subsets Approved Johnson & Johnson IMAAVY (nipocalimab) First fully human anti-FcRn mAb; approved April 2025 for antibody-positive gMG; deep-pocketed competitor Approved (2025) Immunovant Batoclimab / IMVT-1402 Pipeline FcRn; IMVT-1402 touts limited LDL/albumin impact — a potential safety edge Late-stage pipeline
Two things stand out from this landscape. First, competition is real and well-funded — J&J in particular is a formidable entrant with the resources to invest heavily behind nipocalimab, and UCB’s RYSTIGGO is an established competing FcRn option. Immunovant’s IMVT-1402, with its cleaner reported effect on LDL cholesterol and serum albumin at the 300 mg subcutaneous dose, could become a next-generation threat if its differentiated safety profile holds through late-stage trials.
Second, despite the crowd, argenx retains structural advantages that are hard to replicate quickly: the broadest set of approved indications, the largest real-world evidence base, an entrenched prescriber network, and the convenience lead of an approaching autoinjector. In specialty immunology, the first entrant with strong data and a broad label typically holds durable share because switching an established, stable patient carries clinical risk that neurologists are reluctant to take. New entrants generally win new patients at the margin rather than converting existing ones — which slows share erosion even as the market fragments. This is why argenx is better positioned than peers: it is defending an installed base while continuing to expand the pie through new indications and geographies.
—
3. Economic Moat Analysis
Moat Type 1: Switching Costs & Clinical Inertia
The strongest element of argenx’s moat is the switching cost embedded in specialty autoimmune treatment. Once a myasthenia gravis or CIDP patient is stabilized on VYVGART, both the patient and the treating neurologist are strongly disinclined to switch to a competing FcRn inhibitor or a different mechanism. Autoimmune diseases are chronic and unpredictable; a patient who has achieved control faces real clinical risk from any change in therapy, and physicians are conservative about disturbing a working regimen. This inertia is reinforced by argenx’s 18 consecutive quarters of sequential growth, which reflects not just new patient adds but the persistence of the existing base — patients staying on therapy quarter after quarter. The concrete evidence is in the numbers: growing from $1.2 billion (2023) to $2.2 billion (2024) to $4.2 billion (2025) in product net sales is only possible if churn is low and the installed base compounds. A drug with high switching costs and a growing installed base produces exactly this kind of durable, accelerating revenue curve.
Moat Type 2: Platform / Intangible Assets (FcRn leadership)
argenx’s second moat is its position as the pioneer and technical leader of FcRn inhibition. The company defined the category with efgartigimod and holds the deepest development experience, the broadest approved label, and the most mature safety database in the class. This is an intangible-asset moat: regulatory approvals across multiple indications, patent protection on the molecule and formulations, accumulated clinical know-how, and the ability to expand into new indications faster and more cheaply than a company starting from a blank sheet. The subcutaneous autoinjector program (2027) extends this lead into a convenience dimension that later entrants will take years to match. Because the platform is indication-agnostic, each new approval both adds revenue and deepens the intangible moat — more data, more prescriber trust, more label breadth — making the overall position self-reinforcing. The 89.5% gross margin is a direct financial signature of this moat: pricing power and low marginal cost that only a differentiated, hard-to-substitute biologic can command.
Moat Durability Assessment
Will this moat hold over 5–10 years? The honest answer is: mostly yes, but with erosion at the edges. The durability case rests on switching costs, indication breadth, and continued pipeline delivery — all of which are intact and strengthening. The primary risks to the moat are (1) J&J’s nipocalimab and UCB’s RYSTIGGO winning disproportionate share of new patients, gradually capping argenx’s growth even if they don’t convert the existing base; (2) Immunovant’s IMVT-1402 emerging as a genuinely differentiated next-generation FcRn with a superior safety profile, which could reset physician preferences for new starts; and (3) eventual patent expiry and biosimilar competition, though that is a next-decade concern rather than a near-term one. The counterargument is that argenx is not standing still — it is racing to add indications (myositis, MMN, and a broad earlier-stage pipeline), launch the autoinjector, and expand geographically, all of which widen the moat faster than competitors can narrow it. On balance, the moat is durable through the medium term, with the key watch item being whether argenx maintains its share of new patient starts as the field crowds.
—
4. Financial Analysis
argenx’s financial profile has undergone one of the more dramatic transformations in large-cap biopharma: from a cash-burning, clinical-stage company just a few years ago to a highly profitable, self-funding commercial platform today.
Revenue and profitability trajectory (product net sales and TTM totals):
Period Product net sales Notes 2023 ~$1.2B Early multi-geography VYVGART launch 2024 ~$2.2B VYVGART + VYVGART SC; profitability inflection begins 2025 ~$4.2B +90% YoY; sustained profitability TTM (through Q2 2026) $5.22B (total revenue) Net income $1.71B; net margin 32.8% Q2 2026 (quarter) $1.5B +60% YoY; operating profit $494M (+146% YoY)
The trajectory tells a clear story. Product net sales roughly doubled in 2024, nearly doubled again in 2025 (+90%), and the franchise continues to grow 60% year-over-year even at a $5-billion-plus run-rate — remarkable durability of growth at scale. The swing from losses in 2022–2023 to strong profitability in 2024–2025 marks the operating-leverage inflection: because the incremental gross margin on each additional dollar of VYVGART sales is roughly 89 cents, revenue growth flows disproportionately to the bottom line once fixed R&D and commercial infrastructure are covered. Q2 2026 operating profit of $494 million on $1.5 billion of sales — a 146% year-over-year jump versus 60% revenue growth — is the operating leverage in action: profit growing more than twice as fast as revenue.
Key operating metrics specific to the business:
– Gross margin: 89.5% — signature of a differentiated specialty biologic with pricing power.
– Operating margin: 28.8% and net margin: 32.8% (TTM) — already strong for a company still investing heavily in pipeline expansion.
– ROE: 23.6% / ROA: 19.9% — high returns on both equity and assets, indicating efficient capital deployment.
– 18 consecutive quarters of sequential growth — a persistence metric that speaks to installed-base durability.
Balance sheet highlights. The standout figure is a debt-to-equity ratio of 0.01 — argenx is effectively debt-free. Combined with strong and growing operating cash generation (Q2 2026 profit for the period of $472 million), the company is self-funding its pipeline without recourse to debt or dilutive capital raises. This is a materially de-risked balance sheet: there is no refinancing risk, no interest burden, and ample internal capital to fund the myositis, MMN, and broader Immunology Innovation Program studies. For a company still in expansion mode, the ability to fund growth entirely from operating cash flow is a significant quality marker.
Margin expansion story. argenx is past the “path to profitability” stage — it is now in the “margin expansion” stage. As the franchise scales across indications and geographies, and as high-margin subcutaneous self-administration grows as a share of the mix, operating margins should continue to expand from the current high-20s toward the 30s and beyond, assuming R&D reinvestment is disciplined. The tension for investors is that argenx will (appropriately) keep reinvesting heavily in pipeline expansion, which will temper near-term margin expansion in exchange for longer-term indication optionality — a trade-off that favors long-term compounders.
—
5. Valuation
At $1,032.58 per share and a $64.6 billion market capitalization, argenx is priced as a quality growth compounder rather than a speculative biotech. Because the company is solidly profitable, a P/E-based framework anchored on forward consensus earnings is the most appropriate primary method, cross-checked against the analyst consensus target.
Primary method — forward P/E on consensus EPS.
– Consensus EPS next year: $38.44 (verified).
– Current forward P/E: 26.86x ($1,032.58 ÷ $38.44 = 26.86 — self-checked and consistent).
– Trailing EPS is $26.24, for a trailing P/E of 39.35x ($1,032.58 ÷ $26.24 = 39.35 — self-checked).
For a company growing product sales 60% year-over-year with a 33% net margin and a debt-free balance sheet, a forward P/E in the high-20s is not aggressive — the growth-adjusted (PEG-style) multiple is well below 1 if even a fraction of the current growth persists. The valuation debate is really about how quickly growth decelerates and how much pipeline optionality to capitalize.
Scenario analysis (applied to forward EPS of $38.44):
Scenario Forward P/E applied Implied price target vs. current ($1,032.58) Key assumption Bull 34x ~$1,307 +26.6% Myositis/MMN readouts positive; franchise sustains 40%+ growth; multiple re-rates on platform optionality Base 30x ~$1,153 +11.7% Growth decelerates gradually but stays strong; steady indication rollout; margin expansion continues Bear 22x ~$846 -18.1% Competition (J&J, UCB, Immunovant) caps new-patient share; growth halves; multiple compresses
Price target and comparison to consensus. My base-case target is ~$1,153 (30x forward EPS), implying roughly +12% upside, which sits essentially in line with the analyst consensus target of $1,174.28 (+13.7% upside). I broadly agree with the consensus. The post-Q2 analyst target cluster is instructive: RBC at $1,025 and Oppenheimer at $1,037 anchor the cautious end (roughly current price), Leerink at $1,065 and Guggenheim at $1,185 sit near the base case, and Wells Fargo at $1,350 defines the bull end. This spread reflects the core disagreement — not whether VYVGART works, but how much of the multi-indication future to pay for today.
My valuation conclusion: argenx offers a favorable asymmetry if the pending readouts deliver. The base case gives low-double-digit upside to consensus, the bull case (which requires positive myositis/MMN data and sustained 40%+ growth) offers ~27%, and the bear case downside of ~18% is real but bounded by the durable, profitable installed base that provides a valuation floor. Because the stock trades near its 52-week high and much of the near-term good news is priced, this is a Buy on quality and pipeline optionality rather than a deep-value Strong Buy.
—
6. Risk Factors
Risk 1 — Intensifying competition in FcRn and myasthenia gravis (single-franchise concentration). argenx’s revenue is overwhelmingly dependent on the VYVGART/efgartigimod franchise, which makes competitive dynamics the dominant risk. Johnson & Johnson’s IMAAVY (nipocalimab), approved in April 2025 as the first fully human anti-FcRn monoclonal antibody, brings a deep-pocketed competitor with the resources to invest aggressively behind share capture. UCB’s RYSTIGGO covers AChR+ and MuSK+ gMG subsets, but with VYVGART now carrying a serotype-agnostic gMG label (AChR+, MuSK+, LRP4+, and seronegative), that serotype coverage is no longer a differentiator versus VYVGART. Immunovant’s IMVT-1402, with its reported limited impact on LDL cholesterol and serum albumin, could emerge as a next-generation FcRn with a safety edge that reshapes physician preference for new patients. Even if argenx retains its installed base through switching-cost inertia, a loss of new-patient share across these three competitors would gradually cap the growth that the current multiple requires. Because so much value rides on one mechanism and one core molecule, competitive erosion hits the whole thesis, not a single segment.
Risk 2 — Pipeline and clinical-readout risk. A meaningful share of argenx’s valuation rests on pipeline optionality — the expectation that VYVGART and follow-on candidates will keep adding indications. The registrational autoimmune myositis readout (expected 3Q26) and the empasiprubart MMN readout (expected 4Q26) are near-term binary events. A disappointing or mixed readout would not impair the existing commercial franchise, but it would remove a leg of the growth narrative, likely compress the multiple, and could trigger a sharp de-rating given how much optionality is embedded at 27x forward earnings. Biology is unpredictable; even a validated mechanism can fail to hit endpoints in a new indication. Investors buying at current levels are, in part, paying for readouts that have not yet happened.
Risk 3 — Valuation and multiple-compression risk. At a $64.6 billion market cap, a forward P/E of ~27x, and a price near its 52-week high, argenx has limited margin for error. The stock is priced for continued high growth and successful pipeline expansion. Any deceleration in the growth rate (from the current 60% toward more normalized levels), any margin disappointment from heavier-than-expected R&D reinvestment, or a broader biotech/high-multiple selloff could compress the multiple meaningfully. As the bear scenario illustrates, a de-rating to 22x forward earnings implies roughly 18% downside even without any change to the fundamental story — simply a change in what the market is willing to pay. High-quality growth stocks near highs carry this asymmetry: modest fundamental disappointment can produce outsized price reaction because so much is already discounted.
—
7. Conclusion & Exit Plan
Investment rating: Buy. argenx is a high-quality, profitable, debt-free immunology platform leader with a durable, growing installed base and genuine multi-indication optionality. The VYVGART franchise expansion thesis — one validated FcRn molecule scaling across indications and geographies at 60% growth with an 89% gross margin — is intact and strengthening. The reason this is a Buy rather than a Strong Buy is valuation and timing: the stock trades near its 52-week high, base-case upside to consensus is a moderate ~12%, and near-term pipeline readouts introduce binary risk. This is a position to own for the multi-year compounding story, accumulated with discipline rather than chased at the high.
Entry price range with rationale. Given a base-case fair value of ~$1,153 and a current price of $1,032.58, the stock offers acceptable but not exceptional entry value here. A disciplined entry range is $900–$1,000, which would capture pullbacks toward the middle of the 52-week range ($658.60–$1,039.30) and improve the risk/reward before the myositis and MMN readouts. Buying the full position at the current high is less attractive than scaling in on weakness or after de-risking readouts.
Exit conditions:
– Target achieved: Trim on strength. Take roughly 25% off at the base-case target of ~$1,153, and trim a further 25% if the bull-case ~$1,307 is reached — locking in gains where much of the near-term optionality is priced in.
– Fundamental break (stop-loss trigger): Reassess the core thesis if year-over-year product sales growth decelerates below ~25% for two consecutive quarters (signaling the installed base is maturing faster than new indications can offset), or if a pivotal pipeline readout — myositis (3Q26) or MMN (4Q26) — fails, or if a competitor demonstrably captures the majority of new patient starts in a core indication. Any of these would materially weaken the growth-and-optionality case that justifies the current multiple.
– Time-based: Reassess in 6 months or immediately upon each pending registrational readout, whichever comes first.
Summary table:
Item Detail Company argenx SE (ARGX) Current Price $1,032.58 Target Price (base) ~$1,153 Upside ~+12% (to base); consensus $1,174.28 (+13.7%) Rating Buy Key Thesis First-in-class FcRn platform scaling from one drug to a multi-indication autoimmune franchise at 60% growth, 89% gross margin, debt-free Main Risk Single-franchise concentration into an intensifying FcRn field (J&J, UCB, Immunovant) plus binary pipeline readouts
—
This article is for informational purposes only and does not constitute investment advice. All data sourced from public filings, analyst reports, and news as of the publication date. Invest at your own discretion.
This content is general investment information provided to an indefinite/unspecified audience by a quasi-investment advisory business registered under Korea’s Financial Investment Services and Capital Markets Act, and is not personalized 1:1 investment advice tailored to any individual investor. This analysis is for informational purposes only and is not a solicitation to invest. All investment decisions and their consequences rest solely with the investor. The estimates and assumptions in this report are as of the writing date (2026-08-21) and may not materialize depending on market conditions and geopolitical variables. Financial data used reflects sources such as company filings and analyst consensus, and the scenarios and price targets represent the author’s conservative assessment. All investments carry the risk of principal loss, and past performance or analytical track record does not guarantee future results. As of the writing date, the author does not hold a position in this stock. The author’s holdings and positions may change without prior notice depending on market conditions.
함께 읽으면 좋은 글
- Workiva Agentic AI Connected Reporting Platform: Why the GAAP Profitability Inflection and 18x Forward P/E Point to 13% Base-Case Upside (35% Bull)
- Neurocrine Biosciences Beyond Ingrezza: Why the CRENESSITY and VYKAT XR Ramp Points to 37% Upside in 2026
- Advanced Energy Industries (AEIS) Data Center Power Surge: Record Semiconductor Revenue and the Path to a $429 Price Target
- [2026년 08월 재분석] Oceaneering International (OII): Why We Keep Trimming a $51.59 Stock After the $400M–$440M EBITDA Guidance Raise and Citi’s Target Jump to $52
- [2026년 08월 재분석] Applied Materials AMAT Post-Q3 Reset: Why a Record $9.12B Quarter and a De-Rated 27x Forward Multiple Reopen the Path to a $620 Base Case